Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31194792 | 0.98 | CDK2 (0.42) | CDK2NUDT1KDM4DADRA1AKDM4E | |
| SCHEMBL3112689 | 0.81 | NUDT1 (0.41) | NUDT1PDE4APDE3A | |
| SCHEMBL3759218 | 0.81 | NUDT1 (0.41) | NUDT1 | |
| SCHEMBL12618990 | 0.74 | NUDT1 (0.38) | CDK2NUDT1KDM4DKDM4EALDH1A1 | |
| SCHEMBL30549535 | 0.73 | CDK2 (0.61) | CDK2KDM4DADRA1AKDM4EALDH1A1 | |
| SCHEMBL31156498 | 0.72 | CDK2 (0.50) | CDK2NUDT1KDM4DKDM4EALDH1A1 | |
| SCHEMBL31466725 | 0.72 | CYP19A1 (0.36) | CDK2KDM4EALDH1A1CYP19A1TSHR | |
| SCHEMBL15743453 | 0.72 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDCLK4HTT | |
| SCHEMBL26476230 | 0.72 | ADORA3 (0.46) | CDK2KDM4DKDM4EALDH1A1HPGD | |
| SCHEMBL25319736 | 0.71 | SGMS2 (0.38) | CDK2ALDH1A1HTTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805280-B | Heteroaryl compounds for the treatment of huntington's disease | PTC医疗公司 | 2024-12-06 | — | — | CN | claimed |
| EP-3814345-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-09-25 | — | — | EP | claimed |
| EP-2231660-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009086123-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | claimed |
| EP-4739691-A1 | SUBSTITUTED PYRIDYL/PYRAZINYL DIHYDROPYRROLOTRIAZINE COMPOUNDS FOR COMBATTING PHYTOPATH-OGENIC FUNGI | BASF SE (DE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739690-A1 | SUBSTITUTED QUINOLYL/QUINOXALYL DIHYDROPYRROLOTRIAZINE COMPOUNDS FOR COMBATTING PHYTO-PATHOGENIC FUNGI | BASF SE (DE) | 2026-05-13 | — | — | EP | disclosed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025078181-A1 | FUNGICIDAL MIXTURE COMPRISING SUBSTITUTED PYRIDINES | BASF SE (DE) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025078183-A1 | FUNGICIDAL MIXTURE COMPRISING SUBSTITUTED QUINAZOLYL QUINOLINES | BASF SE (DE) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025031843-A1 | NEW SUBSTITUTED BENZOXAZINE PICOLINONITRILE COMPOUNDS FOR COMBATTING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025031842-A1 | NEW SUBSTITUTED BENZOXAZEPINE PICOLINONITRILE COMPOUNDS FOR COMBATTING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025008227-A1 | SUBSTITUTED PYRIDYL/PYRAZINYL DIHYDROPYRROLOTRIAZINE COMPOUNDS FOR COMBATTING PHYTOPATH-OGENIC FUNGI | BASF SE (DE) | 2025-01-09 | — | — | WO | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | CDK2 2559/4885NUDT1 266/4885KDM4D 2949/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | CDK2 1206/4885NUDT1 2468/4885KDM4D 4855/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | CDK2 800/4885NUDT1 2931/4885KDM4D 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.